<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01289483</url>
  </required_header>
  <id_info>
    <org_study_id>10-808</org_study_id>
    <nct_id>NCT01289483</nct_id>
  </id_info>
  <brief_title>Fospropofol for Sedation During Elective Awake Intubation</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>The Cleveland Clinic</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Eisai Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>The Cleveland Clinic</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Patients scheduled for awake fiberoptic intubation (AFI) because of potential difficult
      airway will be consented prior to intubation ASA Physical Status classification and history
      of difficult intubation will be recorded at screening. The investigators will also record the
      results of airway examination including Mallampati classification, thyromental distance,
      mouth opening, neck circumference, neck range of motion, presence or absence of beard and
      overbite, history of neck radiation, and mandibular protrusion test Informed consent will be
      obtained prior to the procedure from those patients who meet the inclusion and exclusion
      criteria.

      Standard hemodynamic monitoring will be used in all patients including EKG, blood pressure,
      heart rate, respiratory rate and oxygen saturation. Modified Observer's Assessment of
      Alertness/Sedation (MOAA/S) scale will be used to assess the level of alertness/sedation. Two
      consecutive MOAA/S scores of 4 will be considered as the desired effect of moderate sedation.

      For AFI procedure, IV will be started and oxygen will be administered. 4 L of oxygen will be
      delivered through nasal canula until the completion of the AFI procedure. Patient head will
      be positioned in the sniffing position, Topical anesthesia would be achieved using the
      topical administration of 4 percent lidocaine using atomized and MaDgic nebulizer, and 2%
      xylocaine Jel applied to the surface of Williams airway in a total dose of lidocaine not
      exceeding 10 mg/kg. Patients will be randomized to one of the four fospropofol treatment
      arms: 2, 3.5, 5, or 6.5 mg/kg
    </textblock>
  </brief_summary>
  <overall_status>Withdrawn</overall_status>
  <why_stopped>
    sponsor has decided not to support this study.
  </why_stopped>
  <start_date>February 2011</start_date>
  <completion_date type="Actual">April 2011</completion_date>
  <primary_completion_date type="Actual">April 2011</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Rescue intubation needed</measure>
    <time_frame>every 4 minutes during procedure, day 1</time_frame>
    <description>Requiring rescue midazolam and or fentanyl to facilitate intubation</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Hypotension</measure>
    <time_frame>every 2 minutes, during procedure, day 1</time_frame>
    <description>Development of hypotension ( defined as blood pressure drop of more than &gt;30 % of base line) and/or hypoxemia ( SaO2 &lt; 90% or a drop of &gt;5% of baseline , whichever is lower)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>hypertension</measure>
    <time_frame>every 2 minutes, during procedure day 1</time_frame>
    <description>Development of hypertension ( increase in blood pressure of &gt; 30% of baseline), and/or tachycardia (120 beat/min or increase in heart rate of &gt; 30% of base line, whichever is higher )</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total dose of midazolam and fentanyl used</measure>
    <time_frame>end of procedure, day 1</time_frame>
    <description>Total dose of midazolam and fentanyl used</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ease of intubation</measure>
    <time_frame>seconds, after intubation, day 1</time_frame>
    <description>anesthesiologists' assessment of ease of intubation on a visual analog scale (VAS) of 0-10, with 0 being very easy, and 10 being very difficult.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient recall and satisfaction</measure>
    <time_frame>end of procedure,day 1</time_frame>
    <description>Patient recall and satisfaction</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to intubate</measure>
    <time_frame>seconds, during procedure, day 1</time_frame>
    <description>Time to intubation ( first fospropofol bolus to positive EtCO2 )</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Failed intubation</measure>
    <time_frame>seconds, day 1</time_frame>
    <description>Failed intubation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>unresponsiveness</measure>
    <time_frame>seconds, during procedure, day 1</time_frame>
    <description>Patient becoming un-responsive and /or requiring bag-mask Ventilation</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">0</enrollment>
  <condition>Impaired Airway Clearance</condition>
  <arm_group>
    <arm_group_label>fospropofol 6.5 mg/kg.</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patient randomized to receive fospropofol for awake intubation at 6.5 mg/kg.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>fospropofol 5 mg/kg.</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patient randomized to receive fospropofol for awake intubation at 5 mg/kg.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>fospropofol 3.5 mg/kg.</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patient randomized to receive fospropofol for awake intubation at 3 mg/kg.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>fospropofol 2 mg/kg.</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patient randomized to receive fospropofol for awake intubation at 2 mg/kg.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>fospropofol</intervention_name>
    <description>After the initial bolus dose of study drug is given, a maximum of two supplemental doses of fospropofol at 25% of the initial dose will be permitted. Fospropofol supplements will be administered every 4 min</description>
    <arm_group_label>fospropofol 6.5 mg/kg.</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>fospropofol</intervention_name>
    <description>After the initial bolus dose of study drug is given, a maximum of two supplemental doses of fospropofol at 25% of the initial dose will be permitted. Fospropofol supplements will be administered every 4 min</description>
    <arm_group_label>fospropofol 5 mg/kg.</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>fospropofol</intervention_name>
    <description>After the initial bolus dose of study drug is given, a maximum of two supplemental doses of fospropofol at 25% of the initial dose will be permitted. Fospropofol supplements will be administered every 4 min</description>
    <arm_group_label>fospropofol 3.5 mg/kg.</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>fospropofol</intervention_name>
    <description>After the initial bolus dose of study drug is given, a maximum of two supplemental doses of fospropofol at 25% of the initial dose will be permitted. Fospropofol supplements will be administered every 4 min</description>
    <arm_group_label>fospropofol 2 mg/kg.</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age: between 18-64 years of age

          -  ASA physical status 1-3 ( Except patients with severe cardiac and/or pulmonary disease

          -  Weight 60-90 Kg

          -  Elective surgery requiring awake FOI

          -  Male or female, female patients should not be pregnant (documented by morning of
             surgery urine pregnancy test result as per routine hospital policy) or lactating

        Exclusion Criteria:

          -  Previous exposure to any experimental drug within 30 days prior to study drug
             administration

          -  Raised intracranial pressure

          -  Patients for whom propofol is contraindicated

          -  Allergy to midazolam and/or fentanyl
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>64 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Basem Abdelmalak, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>The Cleveland Clinic</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Cleveland Clinic</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44195</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 31, 2011</study_first_submitted>
  <study_first_submitted_qc>February 2, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 3, 2011</study_first_posted>
  <last_update_submitted>April 17, 2017</last_update_submitted>
  <last_update_submitted_qc>April 17, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">April 18, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>awake fiberoptic intubation (AFI)</keyword>
  <keyword>difficult airway</keyword>
  <keyword>fospropofol</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fospropofol</mesh_term>
    <mesh_term>Propofol</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

